DILLY STEPHEN GEORGE 4
4 · Sierra Oncology, Inc. · Filed Jul 1, 2022
Insider Transaction Report
Form 4
DILLY STEPHEN GEORGE
DirectorCEO and President
Transactions
- Disposition to Issuer
Common Stock
2022-07-01$55.00/sh−5,000$275,000→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−520,000→ 0 totalExercise: $14.03Exp: 2030-06-01→ Common Stock (520,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−260,000→ 0 totalExercise: $12.15Exp: 2030-08-12→ Common Stock (260,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−92,000→ 0 totalExercise: $16.73Exp: 2031-03-15→ Common Stock (92,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−165,000→ 0 totalExercise: $31.54Exp: 2032-03-14→ Common Stock (165,000 underlying)
Footnotes (5)
- [F1]The option vested as to 25% of the total shares on June 1, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on June 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F2]Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
- [F3]On August 12, 2020, the Reporting Person was granted an option to purchase 260,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
- [F4]The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
- [F5]The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.